Guy Shalom1,2, Devy Zisman3, Meir Babaev4,5, Amir Horev1,2, Shmuel Tiosano5,6, Yochai Schonmann7,8,9, Doron Comaneshter10, Arnon D Cohen10,11. 1. Department of Dermatology and Venereology, Soroka Medical Center, Beer-Sheva, Israel. 2. Division of Medicine, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. 3. Rheumatology Unit, Carmel Medical Center, Bruce and Ruth Rappaport Faculty of Medicine Technion Haifa, Haifa, Israel. 4. Department of Dermatology and Venereology, Sheba Medical Center, Tel-Hashomer, Israel. 5. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 6. Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel. 7. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 8. Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel. 9. Department of Family Medicine, Rabin Medical Center, Clalit Health Services, Tel Aviv, Israel. 10. Chief Physician's Office, Department of Quality Measurements and Research, Clalit Health Services, Tel Aviv, Israel. 11. Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Abstract
BACKGROUND: Updated data regarding the epidemiology of psoriasis and related healthcare utilization are lacking. OBJECTIVE: To investigate the epidemiology, comorbidities, healthcare services utilization, and drug use in a large group of patients with psoriasis from Clalit Health Services (CHS) database. METHODS: A controlled cross-sectional study was performed. Case patients were defined when there was at least one documented diagnosis of psoriasis registered by a CHS dermatologist between the years 1998-2016. The extracted data included metabolic, cardiovascular and psychiatric comorbidities; community clinic visits; in- and outpatient services utilization profiles and drug use data, which included pharmacy claims of topical and systemic treatments, including phototherapy and climatotherapy. Comparative analysis was performed by a univariate and multivariate analysis, adjusting for age, gender, obesity, and smoking. RESULTS: The study included 118,680 patients with psoriasis (prevalence of 2.69%) and 118,680 age- and gender-matched controls. Patients with psoriasis had increased prevalence of metabolic, cardiovascular, and psychiatric illnesses. Psoriasis was significantly associated with an increased healthcare utilization. The mean (SD) number of annual dermatologist clinic visits and emergency room visits was 7.2 ± 12.4 and 2.9 ± 7.7 in psoriasis patients as compared to 2.9 ± 7.9 and 2.7 ± 7.4 in the control group (P < 0.001). Topical steroids were the most applied treatment in psoriasis patients (15.5%), and topical vitamin D analogs were second in use (14.6%). Traditional systemic treatment for psoriasis was used in 3.8% of the patients, and biologic treatments were used in 1.6% of the patients. CONCLUSIONS: Our study quantifies healthcare services utilization and drug use in patients with psoriasis.
BACKGROUND: Updated data regarding the epidemiology of psoriasis and related healthcare utilization are lacking. OBJECTIVE: To investigate the epidemiology, comorbidities, healthcare services utilization, and drug use in a large group of patients with psoriasis from Clalit Health Services (CHS) database. METHODS: A controlled cross-sectional study was performed. Case patients were defined when there was at least one documented diagnosis of psoriasis registered by a CHS dermatologist between the years 1998-2016. The extracted data included metabolic, cardiovascular and psychiatric comorbidities; community clinic visits; in- and outpatient services utilization profiles and drug use data, which included pharmacy claims of topical and systemic treatments, including phototherapy and climatotherapy. Comparative analysis was performed by a univariate and multivariate analysis, adjusting for age, gender, obesity, and smoking. RESULTS: The study included 118,680 patients with psoriasis (prevalence of 2.69%) and 118,680 age- and gender-matched controls. Patients with psoriasis had increased prevalence of metabolic, cardiovascular, and psychiatric illnesses. Psoriasis was significantly associated with an increased healthcare utilization. The mean (SD) number of annual dermatologist clinic visits and emergency room visits was 7.2 ± 12.4 and 2.9 ± 7.7 in psoriasispatients as compared to 2.9 ± 7.9 and 2.7 ± 7.4 in the control group (P < 0.001). Topical steroids were the most applied treatment in psoriasispatients (15.5%), and topical vitamin D analogs were second in use (14.6%). Traditional systemic treatment for psoriasis was used in 3.8% of the patients, and biologic treatments were used in 1.6% of the patients. CONCLUSIONS: Our study quantifies healthcare services utilization and drug use in patients with psoriasis.
Authors: Mohamed Hussein Medhat El-Komy; Heba Mashaly; Khadiga S Sayed; Vanessa Hafez; Marwa S El-Mesidy; Eman R Said; Marwa A Amer; Aya M AlOrbani; Dina G Saadi; Mona El-Kalioby; Reem O Eid; Yousra Azzazi; Hagar El Sayed; Nesrin Samir; Marwa R Salem; Eman D El Desouky; Hesham Abd El-Moaty Zaher; Hoda Rasheed Journal: JAAD Int Date: 2020-07-21
Authors: C Lecaros; J Dunstan; F Villena; D M Ashcroft; R Parisi; C E M Griffiths; S Härtel; J T Maul; C De la Cruz Journal: Clin Exp Dermatol Date: 2021-06-26 Impact factor: 3.470